New drug combo tested for Tough-to-Treat pancreatic cancer
NCT ID NCT07235202
Summary
This study is testing a new drug called MR001, given alongside standard chemotherapy, for people with advanced pancreatic cancer that has gotten worse after their first treatment. The main goals are to find a safe dose of MR001 and to get an early look at whether the combination can help control the cancer. It will involve about 45 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, Beijing Municipality, 102218, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.